Cognoa targets De Novo authorization for its autism diagnostic after reporting strong pivotal study results

The company said that its tool was " highly accurate " in a 425-participant study conducted across 14 U.S. sites.
Source: mobihealthnews - Category: Information Technology Source Type: news